Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Shares Outstanding (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Shares Outstanding for 7 consecutive years, with $229.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 8.11% to $229.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $229.4 million through Dec 2025, up 8.11% year-over-year, with the annual reading at $229.4 million for FY2025, 8.11% up from the prior year.
  • Shares Outstanding hit $229.4 million in Q4 2025 for Allogene Therapeutics, up from $223.2 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $229.4 million in Q4 2025 to a low of $22.0 million in Q1 2022.
  • Historically, Shares Outstanding has averaged $168.3 million across 5 years, with a median of $167.7 million in 2023.
  • Biggest five-year swings in Shares Outstanding: grew 1.12% in 2022 and later rose 28.25% in 2025.
  • Year by year, Shares Outstanding stood at $142.6 million in 2021, then rose by 1.27% to $144.4 million in 2022, then grew by 16.76% to $168.6 million in 2023, then grew by 25.83% to $212.2 million in 2024, then grew by 8.11% to $229.4 million in 2025.
  • Business Quant data shows Shares Outstanding for ALLO at $229.4 million in Q4 2025, $223.2 million in Q3 2025, and $220.1 million in Q2 2025.